{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:04:11Z","timestamp":1794708251355,"version":"4.9.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032682","name":"Department of Clinical Biochemistry, Aarhus University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032682","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.atherosclerosis.2026.120798","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:58:45Z","timestamp":1779951525000},"page":"120798","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Elevated remnant cholesterol, but not LDL cholesterol, explains part of recurrent ASCVD events in individuals with and without impaired renal function: the Copenhagen General Population Study and the UK Biobank"],"prefix":"10.1016","volume":"418","author":[{"given":"Fie","family":"Pilsgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frida","family":"Emanuelsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe","family":"Vedel-Krogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge Gr\u00f8nne","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9562-2897","authenticated-orcid":false,"given":"Camilla Jannie","family":"Kobylecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"34","key":"10.1016\/j.atherosclerosis.2026.120798_bib1","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2026.120798_bib2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1525-139X.2009.00661.x","article-title":"Causes of dysregulation of lipid metabolism in chronic renal failure","volume":"22","author":"Vaziri","year":"2009","journal-title":"Semin Dial"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2026.120798_bib3","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","article-title":"Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease","volume":"18","author":"Matsushita","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2026.120798_bib4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.kint.2016.09.049","article-title":"Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review","volume":"91","author":"Mathew","year":"2017","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120798_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12933-021-01247-0","article-title":"Risk for recurrent cardiovascular disease events among patients with diabetes and chronic kidney disease","volume":"20","author":"Hubbard","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2026.120798_bib6","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1161\/ATVBAHA.124.321387","article-title":"Impaired renal function with higher remnant cholesterol related to risk of atherosclerotic cardiovascular disease: a cohort Study","volume":"44","author":"Elias-Lopez","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2026.120798_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119241","article-title":"Association of low-grade inflammation and elevated remnant cholesterol with risk of ASCVD and mortality in impaired renal function","volume":"406","author":"Elias-Lopez","year":"2025","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2026.120798_bib8","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.atherosclerosis.2026.120798_bib9","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2507227","article-title":"Targeting APOC3 with Olezarsen in moderate hypertriglyceridemia","volume":"393","author":"Bergmark","year":"2025","journal-title":"N Engl J Med"},{"issue":"10493","key":"10.1016\/j.atherosclerosis.2026.120798_bib10","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(25)00825-6","article-title":"Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b\/2a clinical studies","volume":"405","author":"Cummings","year":"2025","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2026.120798_bib11","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/s41591-025-03830-4","article-title":"Targeting the angiopoietin-like protein 3\/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial","volume":"31","author":"Gaudet","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.atherosclerosis.2026.120798_bib12","first-page":"1","article-title":"Remnant cholesterol lowering in cardiovascular disease risk reduction in statin, ezetimibe, and PCSK9 inhibitor trials: meta-regression analyses","author":"Nordestgaard","year":"2025","journal-title":"Eur J Prev Cardiol"},{"issue":"10489","key":"10.1016\/j.atherosclerosis.2026.120798_bib13","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0140-6736(25)00507-0","article-title":"Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Ray","year":"2025","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2026.120798_bib14","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"issue":"10263","key":"10.1016\/j.atherosclerosis.2026.120798_bib15","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(20)32233-9","article-title":"Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort","volume":"396","author":"Mortensen","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2026.120798_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2026.120798_bib17","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2026.120798_bib18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/clinchem\/hvad199","article-title":"Extensive evidence supports the Martin-Hopkins equation as the LDL-C calculation of choice","volume":"70","author":"Grant","year":"2024","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2026.120798_bib19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/clinchem\/hvad190","article-title":"The Sampson-NIH equation is the preferred calculation method for LDL-C","volume":"70","author":"Sampson","year":"2024","journal-title":"Clin Chem"},{"key":"10.1016\/j.atherosclerosis.2026.120798_bib20","series-title":"Regression modeling strategies: with applications to Linear models, logistic regression, and survival analysis","author":"Harrell","year":"2001"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2026.120798_bib35","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.jacc.2024.03.423","article-title":"Excess Apolipoprotein B and Cardiovascular Risk in Women and Men","volume":"83","author":"Johannesen","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120798_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ije\/dyy236","article-title":"Med4way: a Stata command to investigate mediating and interactive mechanisms using the four-way effect decomposition","volume":"48","author":"Discacciati","year":"2019","journal-title":"Int J Epidemiol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2026.120798_bib22","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/EDE.0000000000000121","article-title":"A unification of mediation and interaction: a 4-way decomposition","volume":"25","author":"VanderWeele","year":"2014","journal-title":"Epidemiology"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2026.120798_bib23","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1194\/jlr.M011163","article-title":"Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease","volume":"52","author":"Ooi","year":"2011","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2026.120798_bib24","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-Rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2026.120798_bib25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.atherosclerosis.2026.120798_bib26","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/eurheartj\/ehac822","article-title":"Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality","volume":"44","author":"Wadstrom","year":"2023","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2026.120798_bib27","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/01.ATV.15.4.534","article-title":"Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media","volume":"15","author":"Nordestgaard","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2026.120798_bib28","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.atherosclerosis.2026.120798_bib29","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/heartjnl-2017-312794","article-title":"Coronary heart disease risk associated with the dyslipidaemia of chronic kidney disease","volume":"104","author":"Lamprea-Montealegre","year":"2018","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120798_bib30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/joim.13059","article-title":"Contribution of remnant cholesterol to cardiovascular risk","volume":"288","author":"Langsted","year":"2020","journal-title":"J Intern Med"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120798_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2011","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.atherosclerosis.2026.120798_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120479","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"409","author":"Mach","year":"2025","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2026.120798_bib33","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.ajkd.2018.11.010","article-title":"Lipids, apolipoproteins, and risk of atherosclerotic cardiovascular disease in persons with CKD","volume":"73","author":"Bajaj","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"19","key":"10.1016\/j.atherosclerosis.2026.120798_bib34","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jacc.2025.02.035","article-title":"Target populations for novel triglyceride-lowering therapies","volume":"85","author":"Nordestgaard","year":"2025","journal-title":"J Am Coll Cardiol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026001644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026001644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:00:53Z","timestamp":1782176453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915026001644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":35,"alternative-id":["S0021915026001644"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120798","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated remnant cholesterol, but not LDL cholesterol, explains part of recurrent ASCVD events in individuals with and without impaired renal function: the Copenhagen General Population Study and the UK Biobank","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120798","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120798"}}